Gilteritinib Archives - Medical Conferences

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib

Presented By

Dr Mark Levis, Johns Hopkins Hospital, Maryland, USA

Trial

MORPHO

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:45

Excellent results for triplet regimen in FLT3-mutated AML

Presented By

Prof. Nicholas Short, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:25

Comparable outcomes with gilteritinib or quizartinib in R/R AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, QuANTUM-R

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:14

Gilteritinib in R/R AML patients priorly treated with midostaurin or sorafenib

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

CHRYSALIS, ADMIRAL

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:07

Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, ADMIRAL

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:14